RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 Nov 2024 17:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 Aug 2024 07:02:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 Jul 2024 08:10:21 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 Jun 2024 07:00:14 By Nasdaq GlobeNewswire